FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2159192064> ?p ?o ?g. }

• W2159192064 endingPage "272" @default.
• W2159192064 startingPage "260" @default.
• W2159192064 abstract "Cardiovascular Drug ReviewsVolume 15, Issue 3 p. 260-272 Free Access Renal Effects of SCH 54470: A Triple Inhibitor of ECE, ACE, and NEP Subbarao Vemulapalli, Corresponding Author Subbarao Vemulapalli Schering-Plough Research Institute, Kenilworth, NJ 07033Address correspondence and reprint requests to Dr. S. Vemulapalli, Schering-Plough Research Institute, 2015 Galloping Hill Rd., Kenilworth, NJ 07033. Fax: (908) 298-3294.Search for more papers by this authorMadhu Chintala, Madhu Chintala Schering-Plough Research Institute, Kenilworth, NJ 07033Search for more papers by this authorAndrew Stamford, Andrew Stamford Schering-Plough Research Institute, Kenilworth, NJ 07033Search for more papers by this authorRobert Watkins, Robert Watkins Schering-Plough Research Institute, Kenilworth, NJ 07033Search for more papers by this authorPeter Chiu, Peter Chiu Schering-Plough Research Institute, Kenilworth, NJ 07033Search for more papers by this authorEdmund Sybertz, Edmund Sybertz Schering-Plough Research Institute, Kenilworth, NJ 07033Search for more papers by this authorAhmad B. Fawzi, Ahmad B. Fawzi Schering-Plough Research Institute, Kenilworth, NJ 07033Search for more papers by this author Subbarao Vemulapalli, Corresponding Author Subbarao Vemulapalli Schering-Plough Research Institute, Kenilworth, NJ 07033Address correspondence and reprint requests to Dr. S. Vemulapalli, Schering-Plough Research Institute, 2015 Galloping Hill Rd., Kenilworth, NJ 07033. Fax: (908) 298-3294.Search for more papers by this authorMadhu Chintala, Madhu Chintala Schering-Plough Research Institute, Kenilworth, NJ 07033Search for more papers by this authorAndrew Stamford, Andrew Stamford Schering-Plough Research Institute, Kenilworth, NJ 07033Search for more papers by this authorRobert Watkins, Robert Watkins Schering-Plough Research Institute, Kenilworth, NJ 07033Search for more papers by this authorPeter Chiu, Peter Chiu Schering-Plough Research Institute, Kenilworth, NJ 07033Search for more papers by this authorEdmund Sybertz, Edmund Sybertz Schering-Plough Research Institute, Kenilworth, NJ 07033Search for more papers by this authorAhmad B. Fawzi, Ahmad B. Fawzi Schering-Plough Research Institute, Kenilworth, NJ 07033Search for more papers by this author First published: 02 April 2007 https://doi.org/10.1111/j.1527-3466.1997.tb00335.xCitations: 15AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat REFERENCES 1 Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77: 1993– 2000. 2 Bazil MK, Rodney W, Lappe W, Webb RL. Pharmacologic characterization of an endothelinA (ETA) receptor antagonist in conscious rats. J Cardiovasc Pharmacol 1992; 20: 940– 948. 3 Benigni A, Perico N, Gaspari F, et al. Increased renal endothelin production in rats with reduced renal mass. Am J Physiol 1991; 260: F331– F339. 4 Benigni A, Zoja C, Corna D, et al. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 1993; 44: 440– 444. 5 Bird JE, Moreland S, Waldron TL, Powell JR. Antihypertensive effects of a novel endothelin-A receptor antagonist in rats. Hypertension 1995; 25: 1191– 1195. 6 Brooks DP, Contino LC, Storer B, Ohlstein EH. Increased endothelin excretion in rats with renal failure induced by partial nephrectomy. Br J Pharmacol 1991; 104: 987– 989. 7 Brooks DP, Depalma D, Gellai M, et al. Nonpeptide endothelin receptor antagonists. III. Effect of SB 209670 and BQ 123 on acute renal failure in anesthetized dogs. J Pharmacol Exp Ther 1994; 271: 769– 775. 8 Clozel M, Breu V, Gray GA, et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994; 270: 228– 235. 9 Cole BR, Kuhnline MA, Needleman P. Atriopeptin III. A potent natriuretic, diuretic, and hypotensive agent in rats with chronic renal failure. J Clin Invest 1985; 76: 2413– 2415. 10 Cushman DW, Cheung HS. Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem Pharmacol 1971; 20: 1637– 1648. 11 Ergul S, Parish DC, Puett D, Ergul A. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension 1996; 28: 652– 655. 12 Fawzi AB, Cleven R, Wright DL. A rapid and selective endothelin-converting enzyme assay: Characterization of a phosphoramidon-sensitive enzyme from guinea pig lung membrane. Analyt Biochem 1994; 222: 342– 350. 13 Firth JD, Raine AEG, Ratcliffe PJ, Ledingham JGG. Endothelin: An important factor in acute renal failure. Lancet 1988; 2: 1179– 1182. 14 Gellai M, Jugus M, Fletcher, Dewolf R, Nambi P. Reversal of postischemic acute renal failure with a selective endothelinA antagonist in the rat. J Clin Invest 1994; 93: 900– 906. 15 Gellai M, Jugus M, Fletcher T, et al. Nonpeptide endothelin receptor antagonists V: Prevention and reversal of acute renal failure in the rat by SB 209670. J Pharmacol Exp Ther 1995; 275: 200– 206. 16 Heida HS, Gomez-Sanchez CE. Hypoxia increases endothelin release in bovine endothelial cells in culture, but epinephrine, norepinephrine, serotonin, histamine and angiotensin II do not. Life Sci 1990; 47: 247– 251. 17 Ihara M, Noguchi K, Saeki T, et al. Biological profiles of highly potent novel endothelin antagonists selective for ETA receptor. Life Sci 1992; 50: 247– 255. 18 King AJ, Brenner BM, Anderson S. Endothelin: A potent and systemic vasoconstrictor peptide. Am J Physiol 1989; 256: F1051– F1058. 19 Kitamura K, Tanaka T, Kato J, Eto T, Tanaka K. Regional distribution of immunoreactive endothelin in porcine tissue: Abundance in inner medulla of the kidney. Biochem Biophys Res Commun 1989; 161: 348– 352. 20 Kohan D. Endothelin synthesis by rabbit renal tubule cells. Am J Physiol 1991; 261: F221– F226. 21 Kon V, Badar KF. Biological actions and pathophysiological significance of endothelin in the kidney. Kidney Int 1991; 40: 1– 12. 22 Kon V, Yoshioka T, Fogo A, Ichikawa L. Glomerular actions of endothelin in vivo. J Clin Invest 1989; 83: 1762– 1767. 23 Lafferty HM, Gunning M, Silva P, Zimmerman MB, Brenner BM, Anderson S. Enkephalinase inhibition increases plasma atrial natriuretic peptide levels, glomerular filtration rate, and urinary excretion in rats with reduced renal mass. Circ Res 1989; 65: 640– 646. 24 Li JS, Lariviere R, Schiffrin EL. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. Hypertension 1994; 24: 183– 188. 25 Li JS, Schiffrin EL. Effect of chronic treatment of adult spontaneously hypertensive rats with an endothelin receptor antagonist. Hypertension 1995; 25: 495– 500. 26 Lopez-Farre A, Gomez-Garre D, Bernabeu F, Lopez-Hovoa JM. A role for endothelin in the maintenance of post-ischemic renal failure in the rat. J Physiol (London) 1991; 444: 513– 522. 27 Luscher TF, Seo B-G, Bühler FR. Potential role of endothelin in hypertension. Controversy on endothelin in hypertension. Hypertension 1993; 21: 752– 757. 28 McKittrick BA, Stamford AW, Weng X, et al. Design and synthesis of phosphoric acids that triply inhibit endothelin converting enzyme, angiotensin converting enzyme and neutral endopeptidase 24.11. Bioorg Med Chem Lett 1996; 6: 1629– 1634. 29 Mino N, Kobayashi M, Nakajima A, et al. Protective effect of a selective endothelin receptor antagonist, BQ-123, in ischemic acute renal failure in rats. Eur J Pharmacol 1992; 221: 77– 83. 30 Needleman P, Greenwald J. Atriopeptin: A cardiac hormone intimately involved in fluid, electrolyte, and blood pressure homeostasis. N Engl J Med 1986; 314: 828– 834. 31 Ohlstein EH, Beck GR Jr, Douglas SA, et al. Nonpeptide endothelin receptor antagonist. II. Pharmacological characterization of SB 209670. J Pharmacol Exp Ther 1994; 271: 762– 768. 32 Ohta K, Hirata Y, Shichiri M, et al. Urinary excretion of endothelin-1 in normal subjects and patients with renal disease. Kidney Int 1991; 39: 307– 311. 33 Orisio S, Benigni A, Bruzzi I, et al. Renal endothelin gene expression is increased in remnant kidney and correlated with disease progression. Kidney Int 1993; 43: 354– 358. 34 Rakuki H, Tubuchi Y, Nakamaru M, et al. Evidence for endothelin-1 release from resistance vessels of rats in response to hypoxia. Biochem Biophys Res Commun 1990; 169: 973– 977. 35 Shibouta Y, Suzuki N, Shino A, et al. Pathophysiological role of endothelin in acute renal failure. Life Sci 1990; 46: 1611– 1618. 36 Smith S, Anderson S, Ballermann BJ, Brenner BM. Role of atrial natriuretic peptide in adaptation of sodium excretion with reduced renal mass. J Clin Invest 1986; 77: 1395– 1398. 37 Sogabe K, Nirei H, Shobo M, et al. Pharmacological profile of FR 139317, a novel, potent endothelin ETA receptor antagonist. J Pharmacol Exp Ther 1993; 264: 1040– 1046. 38 Stewart DJ, Levy RP, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease? Ann Intern Med 1991; 114: 464– 469. 39 Stockenhuber F, Gottsauner-Wolf M, Marosi L, Liebisch B, Kurz RW, Balcke P. Plasma levels of endothelin in chronic renal failure and after renal transplantation: impact on hypertension and cyclosporin A-associated nephrotoxicity. Clin Sci 1992; 82: 255– 258. 40 Sybertz EJ, Chiu PJS, Vemulapalli S, et al. SCH 39370, a neutral metalloendopeptidase inhibitor, potentiates biological responses to atrial natriuretic factor and lowers blood pressure in desoxycorticosterone acetate-sodium hypertensive rats. J Pharmacol Exp Ther 1989; 250: 624– 631. 41 Tomita K, Naganishi T, Tomura S, et al. Plasma endothelin levels in patients with acute renal failure. N Engl J Med 1989; 324: 1127. 42 Vemulapalli S, Watkins RW, Brown AB, Cook J, Bernardino V, Chiu PJS. Disparate effects of phosphoramidon on blood pressure in SHR and DOCA-salt hypertensive rats. Life Sci 1993; 53: 783– 793. 43 Vemulapalli S, Chiu PJS, Chintala M, Bernardino V. Attenuation of ischemic acute renal failure by phosphoramidon in rats. Pharmacology 1993; 47: 188– 193. 44 Vemulapalli S, Rivelli M, Chiu PJS, Del Prado M, Hey J. Phosphoramidon abolishes the increases in endothelin-1 release induced by ischemia-hypoxia in isolated perfused guinea pig lungs. J Pharmacol Exp Ther 1992; 262: 1062– 1069. 45 Warner TD, Allcock GH, Cordr R, Vane JR. Use of the endothelin antagonists BQ-123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and release of EDRF. Br J Pharmacol 1993; 110: 777– 782. 46 Wilkes BM, Susin M, Mento PF, et al. Localization of endothelin-like immunoreactivity in rat kidneys. Am J Physiol 1991; 260: F913– F920. 47 Wilkes BM, Susin M, Mento PF, et al. Localization of endothelin-like immunoreactivity in rat kidneys. Am J Physiol 1991; 260: F913– F920. 48 Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411– 415. 49 Yoshida Y, Kawamura T, Ikoma F, Fogo A, Ochikawa I. Effects of antihypertensive drugs on glomerular structure and function in uninephrectomized SHR. Kidney Int 1991; 39: 1112– 1117. Citing Literature Volume15, Issue3September 1997Pages 260-272 ReferencesRelatedInformation" @default.
• W2159192064 created "2016-06-24" @default.
• W2159192064 creator A5000734090 @default.
• W2159192064 creator A5030933436 @default.
• W2159192064 creator A5039894397 @default.
• W2159192064 creator A5049017606 @default.
• W2159192064 creator A5053281425 @default.
• W2159192064 creator A5070427580 @default.
• W2159192064 creator A5076828679 @default.
• W2159192064 date "2007-04-02" @default.
• W2159192064 modified "2023-10-04" @default.
• W2159192064 title "Renal Effects of SCH 54470: A Triple Inhibitor of ECE, ACE, and NEP" @default.
• W2159192064 cites W1971808662 @default.
• W2159192064 cites W1972565751 @default.
• W2159192064 cites W1974487639 @default.
• W2159192064 cites W1976502176 @default.
• W2159192064 cites W1977944024 @default.
• W2159192064 cites W1987000855 @default.
• W2159192064 cites W1987464405 @default.
• W2159192064 cites W1994363304 @default.
• W2159192064 cites W1994496908 @default.
• W2159192064 cites W1995862377 @default.
• W2159192064 cites W1997967855 @default.
• W2159192064 cites W1998607094 @default.
• W2159192064 cites W2002661436 @default.
• W2159192064 cites W2007112807 @default.
• W2159192064 cites W2008856935 @default.
• W2159192064 cites W2016080489 @default.
• W2159192064 cites W2028808128 @default.
• W2159192064 cites W2031534703 @default.
• W2159192064 cites W2045434816 @default.
• W2159192064 cites W2055696770 @default.
• W2159192064 cites W2061166679 @default.
• W2159192064 cites W2074402069 @default.
• W2159192064 cites W2076734878 @default.
• W2159192064 cites W2077700858 @default.
• W2159192064 cites W2077873446 @default.
• W2159192064 cites W2085683908 @default.
• W2159192064 cites W2086802480 @default.
• W2159192064 cites W2093655696 @default.
• W2159192064 cites W2105763003 @default.
• W2159192064 cites W2109591901 @default.
• W2159192064 cites W2118846428 @default.
• W2159192064 cites W2155738795 @default.
• W2159192064 cites W2157034872 @default.
• W2159192064 cites W2162804111 @default.
• W2159192064 cites W2416499966 @default.
• W2159192064 doi "https://doi.org/10.1111/j.1527-3466.1997.tb00335.x" @default.
• W2159192064 hasPublicationYear "2007" @default.
• W2159192064 type Work @default.
• W2159192064 sameAs 2159192064 @default.
• W2159192064 citedByCount "15" @default.
• W2159192064 countsByYear W21591920642014 @default.
• W2159192064 countsByYear W21591920642021 @default.
• W2159192064 crossrefType "journal-article" @default.
• W2159192064 hasAuthorship W2159192064A5000734090 @default.
• W2159192064 hasAuthorship W2159192064A5030933436 @default.
• W2159192064 hasAuthorship W2159192064A5039894397 @default.
• W2159192064 hasAuthorship W2159192064A5049017606 @default.
• W2159192064 hasAuthorship W2159192064A5053281425 @default.
• W2159192064 hasAuthorship W2159192064A5070427580 @default.
• W2159192064 hasAuthorship W2159192064A5076828679 @default.
• W2159192064 hasConcept C126322002 @default.
• W2159192064 hasConcept C134018914 @default.
• W2159192064 hasConcept C27016395 @default.
• W2159192064 hasConcept C2779611605 @default.
• W2159192064 hasConcept C71924100 @default.
• W2159192064 hasConcept C84393581 @default.
• W2159192064 hasConceptScore W2159192064C126322002 @default.
• W2159192064 hasConceptScore W2159192064C134018914 @default.
• W2159192064 hasConceptScore W2159192064C27016395 @default.
• W2159192064 hasConceptScore W2159192064C2779611605 @default.
• W2159192064 hasConceptScore W2159192064C71924100 @default.
• W2159192064 hasConceptScore W2159192064C84393581 @default.
• W2159192064 hasIssue "3" @default.
• W2159192064 hasLocation W21591920641 @default.
• W2159192064 hasOpenAccess W2159192064 @default.
• W2159192064 hasPrimaryLocation W21591920641 @default.
• W2159192064 hasRelatedWork W1966504330 @default.
• W2159192064 hasRelatedWork W1966732677 @default.
• W2159192064 hasRelatedWork W1966775726 @default.
• W2159192064 hasRelatedWork W1979139803 @default.
• W2159192064 hasRelatedWork W2030889776 @default.
• W2159192064 hasRelatedWork W2037631372 @default.
• W2159192064 hasRelatedWork W2040058909 @default.
• W2159192064 hasRelatedWork W2132898409 @default.
• W2159192064 hasRelatedWork W2748952813 @default.
• W2159192064 hasRelatedWork W4249176446 @default.
• W2159192064 hasVolume "15" @default.
• W2159192064 isParatext "false" @default.
• W2159192064 isRetracted "false" @default.
• W2159192064 magId "2159192064" @default.
• W2159192064 workType "article" @default.